Elicio Therapeutics (ELTX) vs Werewolf Therapeutics (HOWL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Werewolf Therapeutics (HOWL) has outperformed Elicio Therapeutics (ELTX) over the past year, losing 51.6% versus a loss of 82.8%. Over five years, HOWL leads with a -94.7% price change compared with -97.9% for ELTX. Elicio Therapeutics is the larger company by market cap ($48.4 million vs $47.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELTX | HOWL |
|---|---|---|
| Share price | $1.84 | $0.9723 |
| Market cap | $48.36M | $47.26M |
| 1-day change | +1.66% | +6.86% |
| YTD return | -77.26% | +43.53% |
| 1-year return | -82.79% | -51.60% |
| 5-year return | -97.92% | -94.67% |
| EPS (TTM) | $-2.16 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.00 | $1.85 |
| 52-week low | $1.71 | $0.27 |
| Distance from 52-week high | -88.50% | -47.44% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +642.93% | +619.94% |
| Average volume | 340.72K | 6.80M |
| Shares outstanding | 26.28M | 48.60M |
| Employees | 33 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HOWL has outperformed ELTX by 31.2 percentage points over the past year.
About Elicio Therapeutics
ELTX stock →Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Werewolf Therapeutics
HOWL stock →Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
ELTX vs HOWL FAQ
Which is bigger, Elicio Therapeutics or Werewolf Therapeutics?
Elicio Therapeutics (ELTX) is larger, with a market capitalization of $48.36M compared with $47.26M for Werewolf Therapeutics (HOWL).
Which stock has performed better over the past year, ELTX or HOWL?
HOWL returned -51.60% over the past 12 months, compared with -82.79% for ELTX (price return, excluding dividends). Past performance does not predict future results.
Are Elicio Therapeutics and Werewolf Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.